Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on March 13, 2019. The report covers a specific corporate event occurring on the same date regarding the exercise of common stock purchase warrants.
Key Financial Metrics
- Proceeds from Warrant Exercise: Approximately $3.0 million.
- Exercise Price: $6.60 per share.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these standard financial metrics as this is a current report focused on a single transaction rather than a periodic financial statement.
Material Changes
The material change reported is the receipt of capital from warrant holders. This transaction increases the company's cash position by approximately $3.0 million and increases the number of outstanding common shares, though the specific share count issued is not detailed in the text.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies beyond the announcement of the warrant exercise. No unusual items were disclosed.
Investor Verification Checklist
- Verify the exact number of shares issued upon the exercise of warrants to assess potential dilution.
- Confirm the updated cash balance and liquidity position following the $3.0 million inflow.
- Review the attached press release (Exhibit 99.1) for additional context on the warrant holders or terms.